THE SINGLE BEST STRATEGY TO USE FOR AGO TUMOR

Molecular typing relies on molecular genetic screening and isn't but routinely offered. Molecular subtypes and immunohistochemical surrogate markers in the tumors (HR, HER2, triple detrimental) correlate in about 70%. The differentiation of luminal A and B subtypes by HR standing and proliferation markers like Ki-sixty seven may be valuable, but a